Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4697 | recombinant human interferon Alpha-1b Wiki | 0.41 |
| drug803 | CT-V Wiki | 0.41 |
| drug3587 | Serological screening for IgG and IgM antibodies against COVID-19 Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4488 | favipiravir tablets+chloroquine phosphatetablets tablets Wiki | 0.41 |
| drug4785 | thymosin alpha 1 Wiki | 0.41 |
| drug1522 | Favipiravir tablets Wiki | 0.41 |
| drug2655 | Observation of behavior and COVID-19 infection will be conducted. Wiki | 0.41 |
| drug2094 | LY3832479 Wiki | 0.24 |
| drug2916 | Placebo Wiki | 0.11 |
| drug3319 | Remdesivir Wiki | 0.08 |
Navigate: Correlations HPO
There are 6 clinical trials
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.
Description: A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Measure: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Time: Baseline through Day 60Description: PK: AUC of LY3819253
Measure: Pharmacokinetics (PK): Area Under the Concentration-time Curve (AUC) of LY3819253 Time: Baseline through Day 29Description: PD: Change from Baseline in Viral Load
Measure: Pharmacodynamics (PD): Change from Baseline to Day 29 in Viral Load Time: Baseline, Day 29The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.
Description: Change from Baseline to Day 11 in SARS-CoV-2 Viral Load
Measure: Change from Baseline to Day 11 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Time: Baseline, Day 11Description: Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold
Measure: Percentage of Participants with SARS-CoV-2 Viral Load Greater than a Prespecified Threshold Time: Day 7Description: Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization
Measure: Change from Baseline to Day 11 in SARS-CoV-2 Viral Load Among Participants Enrolled with Recent Symptoms Prior to Randomization Time: Baseline, Day 11Description: Percentage of Participants Demonstrating Symptom Resolution
Measure: Percentage of Participants Demonstrating Symptom Resolution Time: Day 11Description: Percentage of Participants Demonstrating Symptom Improvement
Measure: Percentage of Participants Demonstrating Symptom Improvement Time: Day 11Description: PK: Mean Concentration of LY3819253 and LY3819253 in the Presence of LY3832479
Measure: Pharmacokinetics (PK): Mean Concentration of LY3819253 and LY3819253 in the Presence of LY3832479 Time: Day 29Description: PK: Mean Concentration of LY3832479 in the Presence of LY3819253
Measure: PK: Mean Concentration of LY3832479 in the Presence of LY3819253 Time: Day 29Description: Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related ER Visit, or Death
Measure: Percentage of Participants Who Experience COVID-Related Hospitalization, COVID-Related Emergency Room (ER) Visit, or Death Time: Baseline through Day 85Description: Change from Baseline to Day 7 in SARS-CoV-2 Viral Load
Measure: Change from Baseline to Day 7 in SARS-CoV-2 Viral Load Time: Baseline, Day 7Description: Percentage of Participants Enrolled with Recent Symptoms Prior to Randomization Who Experience COVID-Related Hospitalization, COVID-Related ER Visit, or Death
Measure: Percentage of Participants Enrolled with Recent Symptoms Prior to Randomization Who Experience COVID-Related Hospitalization, COVID-Related ER Visit, or Death Time: Baseline through Day 29The purpose of this study is to evaluate whether LY3819253 prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19) in facility staff and residents in contracted skilled nursing and assisted living facility networks with a high risk of SARS-CoV-2 exposure. Participants with a high risk of SARS-CoV-2 exposure will receive LY3819253 or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn. Participation could last up to 25 weeks and may include up to 19 visits.
Description: Percentage of Participants with SARS-CoV-2 Infection
Measure: Percentage of Participants with SARS-CoV-2 Infection Time: Week 4Description: Percentage of Participants with Moderate or Worse Severity COVID-19
Measure: Percentage of Participants with Moderate or Worse Severity COVID-19 Time: Week 8Description: Percentage of Participants with Mild or Worse Severity COVID-19
Measure: Percentage of Participants with Mild or Worse Severity COVID-19 Time: Week 8Description: Percentage of Participants Who are Hospitalized due to COVID-19
Measure: Percentage of Participants Who are Hospitalized due to COVID-19 Time: Week 8Description: Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death
Measure: Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death Time: Week 8Description: Percentage of Participants Who Die Due to COVID-19
Measure: Percentage of Participants Who Die Due to COVID-19 Time: Week 8This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC.
Description: Oxygen requirements measured by 7 categories (1 = least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.
Measure: Pulmonary ordinal outcome (Stage 1) Time: Day 5Description: Extrapulmonary complications and respiratory dysfunction measured by 7 categories (1= least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.
Measure: Pulmonary+ ordinal outcome (Stage 1) Time: Day 5Description: Sustained recovery defined as being discharged from the index hospitalization, followed by being alive and home for 14 consecutive days prior to Day 90.
Measure: Time from randomization to sustained recovery (Stage 2) Time: Up to Day 90Description: Oxygen requirements measured by 7 categories (1 = least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.
Measure: Pulmonary ordinal outcome Time: Days 1-7, 14 and 28Description: Extrapulmonary complications and respiratory dysfunction measured by 7 categories (1= least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.
Measure: Pulmonary+ ordinal outcome Time: Days 1-7Description: Total of: Respiratory rate (breaths per minute) scored from 0 to +3; Oxygen saturation (%) scored from 0 to +3; Any supplemental oxygen scored from 0 to +2; Temperature scored from 0 to +3; Systolic BP scored from 0 to +3; Heart rate (beats per minute) scored from 0 to +3.; and AVPU (alert, voice, pain, unresponsive) scored from 0 to +3. A higher score denotes a worse outcome.
Measure: Change in New Early Warning (NEW) Score Time: Baseline to Day 5Drug studies often look at the effect one or two drugs have on a medical condition, and involve one company. There is currently an urgent need for one study to efficiently test multiple drugs from more than one company, in people who have tested positive for COVID-19 but who do not currently need hospitalization. This could help prevent disease progression to more serious symptoms and complications, and spread of COVID-19 in the community. This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. Participants in the study will be treated with either a study drug or with placebo.
Description: Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)
Measure: Duration of COVID-19 symptoms (Phase 2) Time: Up to Day 28Description: Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs
Measure: Post-treatment presence of SARS-CoV-2 RNA at Day 3 (Phase 2) Time: Day 3Description: Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs
Measure: Post-treatment presence of SARS-CoV-2 RNA at Day 7 (Phase 2) Time: Day 7Description: Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs
Measure: Post-treatment presence of SARS-CoV-2 RNA at Day 14 (Phase 2) Time: Day 14Description: Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs
Measure: Post-treatment presence of SARS-CoV-2 RNA at Day 21 (Phase 2) Time: Day 21Description: Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs
Measure: Post-treatment presence of SARS-CoV-2 RNA at Day 28 (Phase 2) Time: Day 28Description: ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted ton address medical needs of those with severe COVID-19
Measure: Cumulative incidence of death from any cause or hospitalization (Phase 3) Time: Thru Day 28Description: ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted ton address medical needs of those with severe COVID-19
Measure: Cumulative incidence of death from any cause or hospitalization (Phase 2) Time: Thru Day 28Description: Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)
Measure: Duration of COVID-19 symptoms (Phase 3) Time: Up to Day 28Description: Measured as detectable or undetectable, from participant-collected nasal swabs
Measure: Presence of SARS-CoV-2 RNA (Phases 2 and 3) Time: Thru Day 28Description: Measured from participant-collected nasal swabs
Measure: Level of SARS-Cov-2 RNA (Phases 2 and 3) Time: Thru Day 28Description: Based on symptom severity scores. Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3). For participants who are alive at 28 days and not previously hospitalized, the severity ranking will be based on the area under the curve (AUC) of the symptom score associated with COVID-19 disease over time. Participants hospitalized or who die during follow-up through 28 days will be ranked as worse than those alive and never hospitalized as follows (in worsening rank order): alive and not hospitalized at 28 days; hospitalized but alive at 28 days; and died at or before 28 days.
Measure: COVID-19 severity ranking (Phases 2 and 3) Time: From Day 0 thru Day 28Description: Progression of one or more COVID-19-associated symptoms to a worse status than recorded at study entry, prior to start of investigational product or placebo
Measure: Incidence of ≥1 worsening symptom of COVID-19 (Phases 2 and 3) Time: Thru Day 28Description: Defined as the last day in the participant's study diary on which a temperature ≥ 38°C (100.4°F) was recorded or a potentially antipyretic drug was taken.
Measure: Duration of fever (Phases 2 and 3) Time: Thru Day 28Description: As recorded in participant's study diary
Measure: Time to self-report return to usual (pre-COVID-19) health (Phases 2 and 3) Time: Thru Day 28Description: Measured by pulse oximeter and categorized as <96% versus ≥96%
Measure: Oxygen saturation level (Phase 2) Time: Thru Day 28Description: Measured by AUC and above assay lower limit of quantification
Measure: Level of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2) Time: Days 0, 3, 7, 14, 21 and 28Description: Measured by AUC and above assay lower limit of quantification
Measure: Level of SARS-CoV-2 RNA from saliva (Phase 2) Time: Days 0, 3, 7, 14, 21 and 28Description: Measured by AUC and above assay lower limit of quantification
Measure: Level of SARS-CoV-2 RNA from self-collected nasal swabs (Phase 2) Time: Daily at Days 0-14, plus Days 21 and 28Description: From site-collected NP swabs
Measure: Level of SARS-CoV-2 RNA (Phase 2) Time: Days 3, 7, 14, 21 and 28Description: Measured as detectable or undetectable
Measure: Post-treatment presence of SARS-CoV-2 RNA in saliva (Phase 2) Time: Days 3, 7, 14, 21 and 28Description: Measured from saliva samples
Measure: Post-treatment level of SARS-CoV-2 RNA (Phase 2) Time: Days 3, 7, 14, 21 and 28Description: Analyses of plasma samples collected from placebo-treated participants are not planned
Measure: Concentration of investigational agent (Phase 2 - LY3819253) Time: Days 0, 14, 28, Week 12, Week 24Description: Analyses of plasma samples collected from placebo-treated participants are not planned
Measure: Level of anti-drug antibodies (Phase 2 - LY3819253) Time: Days 0, 14, 28, Week 12, Week 24Description: Area under the concentration-time curve. Analyses of plasma samples collected from placebo-treated participants are not planned
Measure: AUC (Phase 2 - LY3819253) Time: Days 0, 14, 28, Week 12, Week 24Description: Analyses of plasma samples collected from placebo-treated participants are not planned
Measure: Total body clearance (CL) (Phase 2 - LY3819253) Time: Days 0, 14, 28, Week 12, Week 24Description: T1/2. Analyses of plasma samples collected from placebo-treated participants are not planned
Measure: Elimination half-life (Phase 2 - LY3819253) Time: Days 0, 14, 28, Week 12, Week 24Description: Maximum plasma concentration of LY3819253. Analyses of samples collected from placebo-treated participants are not planned
Measure: Cmax (Phase 2 - LY3819253) Time: Days 0, 14, 28, Week 12, Week 24Description: Minimum plasma concentration of LY3819253. Analyses of samples collected from placebo-treated participants are not planned
Measure: Cmin (Phase 2 - LY3819253) Time: Days 0, 14, 28, Week 12, Week 24The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last up to 16 weeks and may include up to six visits to the study center, with a one-week overnight stay.
Description: PK: AUC(0-inf)
Measure: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time 0 to Infinity (AUC[0-inf]) Time: Day 1 through Day 85Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports